AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Upon exercise of the option, AbbVie would pay Aldeyra a $100M upfront cash payment, less previously paid option fees of $6M. In addition, Aldeyra would be eligible to receive up to $300 million in ...
AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
Zacks.com on MSN1h
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug ReproxalapALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class ...
Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular ...
Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...
Upon exercise of the option, AbbVie would pay Aldeyra a $100 million upfront cash payment, less previously paid option fees of $6 million. In addition, Aldeyra would be eligible to receive up to $300 ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
including commercial operations, research and development and manufacturing. He also served as President and Chief Operating Officer, prior to a brief retirement. AbbVie is currently addressing ...
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...
Patent expirations from Brukinsa’s existing competitors may bring biosimilar drugs into the field before Brukinsa reaches its full commercial potential. BeiGene may lose the lawsuit to AbbVie over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback